$17.04
+0.04 (+0.24%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BLCO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
213 interventional · 9 observational · 151 with posted results
Held by 18 tracked-famous managers (ICAHN CARL C, OAKTREE CAPITAL MANAGEMENT LP, D. E. Shaw & Co., Inc., GLENVIEW CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, +13 more) · FINRA short interest 5.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| IC-8 Apthera IOL New Enrollment Post Approval StudyNCT06060041observationalRate of any additional Nd:YAG laser treatments beyond the initial Nd:YAG laser treatment | — | Recruiting | — | Cataract, Presbyopia, Posterior Capsule Opacification | 435 | 2027-09-30 | in 407 d | 2026-01-12 |
| A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic AstigmatismNCT07377474The percentage of eyes that achieve predictability (attempted versus achieved) of MRSE within ± 0.50 DOpen-label · Treatment | Not applicable | Not yet recruiting | Device: TENEO 317 Model 2 (1.28 US) Excimer Laser | Myopic Astigmatism | 32 | Sep 2027 | ≤ 407 d | 2026-01-30 |
| A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive KeratectomyNCT07412496Ocular pain intensity following PRK surgeryRandomized · Double-masked · Treatment | Phase 2 | Not yet recruiting | Drug: Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic vehicle | Pain, Postoperative | 123 | Feb 2027 | ≤ 193 d | 2026-02-17 |
| A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in ChildrenNCT06305663Mean change from baseline in axial length.Randomized · Double-masked · Treatment | Not applicable | Recruiting | Device: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic), CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens | Myopia | 418 | 2027-01-31 | in 165 d | 2025-06-15 |
| Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive KeratectomyNCT06618547Maintenance of BCDVA -Open-label · Treatment | Not applicable | Not yet recruiting | Device: TENEO 317 Model 2 excimer laser | Myopia | 140 | Nov 2026 | ≤ 103 d | 2025-06-15 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy VolunteersNCT06978244Incidence of DLTs (dose-limiting toxicities)Randomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: BL1332 ophthalmic solution, BL1332 ophthalmic vehicle | Ocular Pain | 24 | Nov 2026 | ≤ 103 d | 2026-01-27 |
| Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without AstigmatismNCT05264623The percentage of eyes with Uncorrected Distance Visual Acuity (UDVA) of 20/40 or better at the time of refractive stabilityOpen-label · Treatment | Not applicable | Active, not recruiting | Device: TENEO 317 Model 2 excimer laser | Hyperopia | 140 | 2026-11-20 | in 93 d | 2026-01-23 |
| A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial ParticipantsNCT07717918Ocular pain severity assessed by numeric pain rating scale (NPRS)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: BL1332 eye drops, BL1332 Placebo eye drops | Healthy | 28 | Aug 2026 | ≤ 12 d | 2026-07-21 |
| Revive Toric RWE StudyNCT06785194observationalInvestigator overall satisfaction as assessed by the Investigator Survey | — | Not yet recruiting | Device: REVIVE samfilcon B custom toric contact lenses | Astigmatism | 30 | Jul 2026 | — | 2025-11-28 |
| A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.NCT06565650Mean change from baseline in ECDRandomized · Single-masked · Treatment | Phase 4 | Active, not recruiting | Drug: Miebo, Saline | Dry Eye | 216 | Nov 2025 | — | 2024-12-17 |
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye DiseaseNCT07111013Incidence of Treatment Emergent Adverse EventsOpen-label · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Business Decision | Drug: Lifitegrast/perfluorohexyloctane (PFHO) | Dry Eye Disease | 0 | Apr 2027 | ≤ 254 d | 2025-12-10 |
| Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06333015Mean Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) of first implanted eyes at Post-Operative Visit 4.Randomized · Double-masked · Treatment | Not applicable | Completed | Device: enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL | Cataract | 304 | 2026-06-11actual | — | 2026-07-13 |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseNCT07128628Total corneal fluorescein staining change from baselineRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle, Vehicle, Vehicle | Dry Eye Disease | 443 | 2026-05-28actual | — | 2026-07-14 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular HypertensionNCT07168902Change from baseline in visual field mean deviation in the study eye at Day 28/Exit.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% | Glaucoma | 252 | 2026-05-18actual | — | 2026-07-22 |
| A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens WearNCT07054606Change from baseline (CFB) in CLDEQ-8 score at Visit 4Open-label · Basic science | Phase 4 | Completed | Drug: Perfluorohexyloctane ophthalmic solution | Dry Eye | 104 | 2025-11-03actual | — | 2025-12-18 |
| A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular RednessNCT06803654Ocular redness score (0-4 unit scale, allowing half-unit increments) evaluated by the investigator at Visit 2 (Day 1)Randomized · Single-masked · Treatment | Phase 3 | Completed | Drug: BTOS-HA, Lumify® | Ocular Redness | 578 | 2025-06-29actual | — | 2026-05-28 |
| A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06594185Mean binocular best-corrected distance visual acuity (BCDVA) at Postoperative Visit 1Open-label · Treatment | Not applicable | Completed | Device: enVista Aspire EA or Aspire Toric ETA IOLs | Cataract | 335 | 2025-05-21actual | — | 2026-06-03 |
| A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT06333028observationalMean binocular BCDVA (logMAR) at Visit 1 | — | Completed | Device: enVista Aspire EA IOLs | Cataract | 82 | 2025-03-13actual | — | 2025-05-02 |
| A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive AccuracyNCT06346340results2026-07-06Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Miebo | Dry Eye | 97 | 2025-02-24actual | — | 2026-07-06 |
| Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) LensNCT06479148results2026-05-26Photopic Binocular Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 cm at Post-operative Visit 3Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: No additional clinical evidence is required within the scope of this clinical investigation. No safety concern related to any IOL have been identified | Device: enVista® Aspire™, An IOL with a slightly extended depth of focus, MX60E | Cataract | 27 | 2024-12-12actual | — | 2026-05-26 |
| Study of Safety and Effectiveness of the Boston Orthokeratology Shaping Lens in the Arise Orthokeratology LensNCT05984290results2025-08-24The Rate of Serious Adverse Events at the Subject LevelOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: orthokeratology lens | Myopia | 90 | 2024-06-27actual | — | 2025-08-24 |
| A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye DiseaseNCT06309953results2025-10-21Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Miebo | Dry Eye | 99 | 2024-06-17actual | — | 2025-10-21 |
| Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment AlgorithmNCT04617080Binocular Uncorrected Distance Visual Acuity (UDVA)Randomized · Open-label · Treatment | Not applicable | Completed | Procedure: SUPRACOR Regular, SUPRACOR Strong | Ametropia | 60 | 2024-02-28actual | — | 2024-03-01 |
| A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting SolutionNCT05565937results2025-05-20Overall Comfort Averaged Over All Follow-up VisitsRandomized · Double-masked · Supportive careStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BL-3100-NBR03 multi-purpose solution, renu® Advanced Formula multi-purpose solution | Refractive Ametropia | 295 | 2024-02-28actual | — | 2025-05-20 |
| Effects of NOV03 on the Tear FilmNCT05723770results2025-07-04Thickness of the Mucus-aqueous Tear Film LayerOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: instillation of NOV03 | Dry Eye Disease (DED) | 33 | 2023-12-23actual | — | 2025-07-04 |
| 1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact LensesNCT06053736Mean logMAR Visual Acuity at 6mOpen-label · Other | Not applicable | Completed | Device: REVIVE Contact Lens | Refractive Ametropia | 26 | 2023-12-15actual | — | 2024-01-05 |
| Kalifilcon A Toric Compared to Commercially Available LensesNCT06098937results2024-12-10Primary Gaze Orientation for 5 MinutesRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Kalifilcon Toric Lens, Total1 for Astigmatism, Precision1 for Astigmatism, MyDay Toric | Astigmatism | 30 | 2023-09-27actual | — | 2024-12-10 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic SolutionNCT05815758results2025-07-10Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution | Allergic Conjunctivitis | 512 | 2023-09-18actual | — | 2025-07-10 |
| A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular HypertensionNCT04140279Change From Baseline in Episcleral Venous Pressure (EVP) at Intervals on Days 1 and 8Randomized · Single-masked · Treatment | Phase 4 | Withdrawnsponsor's stated reason: It never started | Drug: Latanoprostene Bunod, Placebo | Ocular Hypertension | 0 | Aug 2023 | — | 2024-03-04 |
| Orientation Characteristics of Daily Disposable Toric Contact LensesNCT06069609results2025-07-01Primary Gaze OrientationRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A Daily Disposable Toric, Acuvue Oasys 1-Day for Astigmatism | Astigmatism | 30 | 2023-08-15actual | — | 2025-07-01 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic ConjunctivitisNCT05591755results2025-07-01Ocular Itching Symptom ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution | Seasonal Allergic Conjunctivitis | 229 | 2023-08-09actual | — | 2025-07-01 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic ConjunctivitisNCT05579730results2025-02-14Ocular ItchingRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle | Allergic Conjunctivitis | 188 | 2023-07-22actual | — | 2025-02-14 |
| Evaluate the Safety and Effectiveness of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular LensNCT03603600results2024-12-24Photopic Monocular Best-corrected Distance Visual Acuity (BCDVA)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: enVista MX60E, enVista MX60EF | Cataract | 501 | 2023-05-04actual | — | 2024-12-24 |
| Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact LensNCT05660577results2024-04-09Proportion of Subjects Agreeing With the Statement "Clear Vision: Near, Far, and In-betweenOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens | Myopia and Hyperopia and Presbyopia | 301 | 2023-01-16actual | — | 2024-04-09 |
| Retrospective Chart Review of enVista Toric 0.9D Intraocular LensesNCT05075746results2024-03-21observationalMean Reduction in Cylindrical Power of the EyeStudy Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: enVista Toric, enVista non-Toric (spherical) | Corneal Astigmatism | 302 | 2023-01-03actual | — | 2024-03-27 |
| "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"NCT05360784results2024-08-26Ocular RednessRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%) | Ocular Redness | 380 | 2022-11-23actual | — | 2024-08-26 |
| Evaluation of Visual Acuity of the Envista One-piece Acrylic Toric IOL MX60ETNCT05739656observationalPrimary Effectiveness Endpoint | — | Completed | Procedure: CATARACT SURGERY | Astigmatism | 100 | 2022-07-06actual | — | 2023-02-22 |
| Clinical Study to Evaluate the Safety and Performance of the enVista® One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT04224155results2024-04-18Serious Adverse EventsRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: enVista MX60EFH trifocal intraocular lenses (IOLs), enVista MX60E monofocal intraocular lenses (IOLs) | Cataract | 165 | 2022-06-14actual | — | 2024-10-10 |
| 1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for AstigmatismNCT05320042Visual AcuityRandomized · Double-masked · Treatment | Not applicable | Completed | Device: kalifilcon A Daily Disposable Toric, Ultra for Astigmatism Contact Lenses | Myopia, Astigmatism | 28 | 2022-05-10actual | — | 2022-11-17 |
| 1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for PresbyopiaNCT05325931results2026-08-06Visual Acuity (Distance)Randomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A Daily Disposable Multifocal, samfilcon A for Presbyopia | Presbyopia | 30 | 2022-03-28actual | — | 2026-08-06 |
| Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy TreatmentNCT04698174Absolute refractive predictabilityRandomized · Single-masked · Treatment | Not applicable | Completed | Procedure: Transepithelial Photorefractive keratectomy (tPRK) without laser polishing, Transepithelial Photorefractive keratectomy (tPRK) with laser polishing, Standard Photorefractive keratectomy (PRK) | Ametropia | 39 | 2022-03-21actual | — | 2022-10-07 |
| A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50NCT04192630results2024-05-28Percentage of Participants Who Experienced at Least One Intraocular Pressure (IOP) Measurement ≥30 Millimeters of Mercury (mmHg) at Any Post-Surgical Follow-up VisitRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: CVisc50 OVD, ProVisc OVD · Procedure: Cataract Surgery | Cataract | 390 | 2022-01-31actual | — | 2024-05-28 |
| Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact LensesNCT05129124results2025-07-10Mean Absolute Primary Gaze Orientation at 3 Minutes for the Lenses Inserted at 90 DegreesRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses, Commercially available Ultra for Astigmatism Contact Lenses | Astigmatism | 30 | 2022-01-13actual | — | 2025-07-10 |
| Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)NCT04140227results2023-12-29Number of Participants With Ocular and Non-ocular Adverse EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NOV03 | Dry Eye Disease (DED) | 256 | 2022-01-05actual | — | 2024-03-04 |
| Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric LensesNCT05129072results2025-06-24Spherical Aberration MeasurementOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D | Contact Lens Wearer | 75 | 2021-09-24actual | — | 2025-06-24 |
| 2-Hour Dispensing Evaluation of Samfilcon A Lenses With EPG01 Packaging Solution Compared to Commercially Available B+L Ultra LensesNCT05126953results2025-07-20Normalized logMAR Visual AcuityRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: samfilcon A Lenses with EPG01 Packaging Solution, Commercially Available B+L Ultra Lenses | Contact Lens Wearer | 30 | 2021-09-23actual | — | 2025-07-20 |
| Biotrue ONEday Contact Lenses With EPG03 Packaging Solution Compared to Biotrue ONEday Contact LensesNCT05129488results2024-04-16Normalized logMAR Visual AcuityOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: All participants received Biotrue ONEday lenses with and without an alternate packaging solution (EPG03) | Contact Lens Wearer | 33 | 2021-09-20actual | — | 2024-04-16 |
| Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)NCT04567329results2024-08-19Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57Randomized · Double-masked · TreatmentStudy Protocol ↗ · Study Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NOV03, Saline Solution | Dry Eye Disease | 620 | 2021-08-30actual | — | 2024-08-19 |
| A Study With Technolas® TENEO 317 Model 2 Excimer Laser to Treat Participants With Myopia or Myopic AstigmatismNCT04111757results2024-06-14Percentage of Eyes That Achieve MRSE Predictability Within ±0.50 Diopter (D) and ±1.00 DOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Technolas® TENEO 317 Model 2 | Myopia, Myopic Astigmatism | 168 | 2021-08-06actual | — | 2024-06-14 |
| Surface Refractive Index Shift of Kalifilcon A Compared With Dailies Total1 and Precision1 LensesNCT04840563results2026-08-05Surface Refractive Index of Worn LensesOpen-label · Basic scienceStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A daily disposable spherical soft contact lens, Dailies Total1 (delefilcon A) daily disposable spherical soft contact lens, Precision1 (verofilcon A) daily disposable spherical soft contact lens | Contact Lens Wear | 10 | 2021-04-15actual | — | 2026-08-05 |
| Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)NCT04139798results2024-10-23Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: NOV03, Placebo | Dry Eye Disease (DED) | 599 | 2021-03-12actual | — | 2024-10-23 |
| Safety and IOP-Lowering Effects of WB007NCT04149899results2023-03-24Part 2: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 14 - Study EyeRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5% | Glaucoma, Primary Open Angle, Ocular Hypertension | 77 | 2021-01-31actual | — | 2025-03-27 |
| Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday LensesNCT04555031results2021-11-08Surface Refractive Index Shifts at 5 MinutesRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A lenses, Dalies Total 1, Precision 1, Biotrue ONEday | Habitual Soft Contact Lens Use | 10 | 2020-09-16actual | — | 2021-11-08 |
| A Safety and Effectiveness Study of a New Preservative Free Rewetting DropNCT04175340results2024-07-10Overall Comfort Averaged Over All Follow-up VisitsRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: BL-300-PFM04, OPTI-FREE | Contact Lens Wear | 369 | 2020-02-17actual | — | 2024-07-10 |
| Evaluate the Safety and Effectiveness of the Biotrue ONEday for AstigmatismNCT03681808results2020-12-17Proportion of Participants Achieving a Contact Lens Corrected Distance logMAR VA of 0.04 or BetterRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Control, Test | Astigmatism | 242 | 2019-12-16actual | — | 2021-01-08 |
| Extension Study to Gather Data on Effect of Macugen on the Corneal EndotheliumNCT01573572results2020-10-14Change From Baseline in Mean Endothelial Cell DensityOpen-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: pegaptanib sodium injection | Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema | 131 | 2019-11-14actual | — | 2021-01-08 |
| A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact LensNCT04158466results2020-11-19Mean logMAR Contact Lens Visual AcuityRandomized · Single-masked · Supportive careStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Kalifilcon A Daily Disposable Contact Lenses, Biotrue ONEday Daily Disposable Contact Lenses | Contact Lens Wear | 252 | 2019-11-12actual | — | 2020-11-19 |
| Product Performance of a New Silicone Hydrogel Contact LensNCT04901897results2021-07-08Mean Change in logMAR Contact Lens Visual AcuityRandomized · Single-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: kalifilcon A, delefilcon A, senofilcon A | Myopia | 805 | 2019-10-09actual | — | 2021-07-08 |
| A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Custom Contact Lens When Compared to Alden Optical HP Sphere LensNCT03897712results2022-10-26Mean Distance High-contrast logMAR Lens VARandomized · Double-masked · Supportive careStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Custom Samfilcon B Contact Lenses, Alden Optical HP Sphere Contact Lens, ReNu MultiPlus Lubricating and Rewetting Drops, Biotrue Multi-Purpose Solution | Contact Lens Wear | 84 | 2019-08-28actual | — | 2022-11-14 |
| Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOLNCT02394379observationalIncidence of clinically significant IOL vaulting | — | Completed | Device: Trulign™ Toric IOL | Cataract | 600 | 2019-08-05actual | — | 2019-11-13 |
| A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact LensesNCT03897751results2022-11-30Overall ComfortRandomized · Double-masked · Supportive careStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: ABT12 Multi-Purpose Solution, COMPLETE Multi-Purpose Solution, Sensitive Eyes® Rewetting Drops | Contact Lens Wear | 252 | 2019-08-01actual | — | 2023-03-03 |
| Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)NCT03511638results2021-10-22Percent Change in Mean Epithelial Cell Density (ECD)Randomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Bausch & Lomb DVisc40, Alcon VISCOAT® | Cataract | 372 | 2019-04-01actual | — | 2021-10-22 |
| Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide ImplantNCT01060787observationalCorneal Endothelial Cell Density | — | Completed | Procedure: Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg | Inflammation, Uveitis | 98 | 2019-03-07actual | — | 2019-06-21 |
| Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT03896633results2021-06-09Intraocular Pressure (IOP)Randomized · Double-masked · Health services researchStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: brinzolamide 1% ophthalmic suspension, Azopt 1% | Glaucoma, Open Angle or Ocular Hypertension | 637 | 2018-11-17actual | — | 2023-05-09 |
| Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)NCT03282929CmaxRandomized · Open-label · Treatment | Phase 1 | Completed | Device: Part 1, Part 2 Group 1, Part 2 group 3, Part 2 Group 4 · Drug: Part 2 group 2 | Anaphylaxis | 43 | 2018-09-28actual | — | 2019-06-21 |
| Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal ImplantNCT03145025observationalThe primary safety endpoint is change from baseline in endothelial cell density (ECD) in the study eye one year following implantation. | — | Completed | Device: Retisert · Drug: Fluocinolone Acetonide Intravitreal Implant | Uveitis, Posterior | 3 | 2018-09-10actual | — | 2019-06-21 |
| A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and VehicleNCT03489941results2021-05-17Ocular ItchingRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: EM-100, Zaditor®, Vehicle | Allergic Conjunctivitis | 65 | 2018-04-29actual | — | 2023-06-08 |
| Clinical Study of Approved Contact LensesNCT03351101results2020-09-16End of Day ComfortRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Senofilcon C, Samfilcon A | Myopia | 271 | 2017-11-10actual | — | 2021-01-08 |
| LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT02786901results2020-04-14Number of Participants With Complete Resolution of Anterior Chamber (AC) Cells at Visit 5 (Postoperative Day 8)Randomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol Etabonate Ophthalmic Gel dosed BID, Vehicle Gel | Cataract, Pain, Ocular Inflammation | 600 | 2017-06-13actual | — | 2021-01-08 |
| Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.NCT01475643results2019-06-11Anterior Chamber InflammationRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Loteprednol etabonate, Prednisolones acetate | Cataract | 107 | 2017-06-02actual | — | 2019-06-11 |
| Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular InstallationsNCT03098953PK analysis will be performed using standard non compartmental methodOpen-label · Treatment | Phase 1 | Completed | Drug: Loteprednol Etabonate | Healthy | 15 | 2017-05-12actual | — | 2017-05-18 |
| Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal AstigmatismNCT01852084results2020-09-16Mean Dioptric Change in CylinderRandomized · Double-masked · Treatment | Not applicable | Completed | Device: enVista® One-Piece Hydrophobic Acrylic Toric IOL, enVista control lens | Astigmatism | 191 | 2016-07-18actual | — | 2020-09-16 |
| A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting SolutionNCT02701556results2017-05-31The Primary Safety Endpoint Was Statistical Non-inferiority With Respect to the Proportion of Eyes With Any Slit Lamp Findings Greater Than Grade 2 at Any Visit Between the Test and Control Solutions.Randomized · Triple-masked · Treatment | Not applicable | Completed | Device: Complete MPS, NNR06 | Contact Lens Wear | 396 | 2015-10-31actual | — | 2022-02-08 |
| A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%NCT01437982SafetyRandomized · Triple-masked · Treatment | Phase 4 | Completed | Drug: Loteprednol Etabonate, Prednisolone Acetate 1% Oph Susp | Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation | 140 | 2015-10-19actual | — | 2019-11-19 |
| Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular LensNCT01615861Visual AcuityOpen-label · Other | Not applicable | Completed | Procedure: IOL implantation · Device: IOL Implantation | Cataract | 103 | 2015-06-16actual | — | 2019-11-14 |
| Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749904results2018-11-07Mean IOPRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: BOL-303259-X, Timolol, BOL-303259-X | Open-Angle Glaucoma, Ocular Hypertension | 420 | 2015-06-02actual | — | 2018-11-07 |
| Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01749930results2018-11-21Mean IOPRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: BOL-303259-X, Timolol, BOL-303259-X | Open-Angle Glaucoma, Ocular Hypertension | 420 | May 2015actual | — | 2018-11-21 |
| Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHTNCT01895972results2018-06-06Change From Baseline in Intraocular PressureOpen-label · Treatment | Phase 3 | Completed | Drug: Latanoprostene bunod | Glaucoma, Ocular Hypertension | 130 | 2015-04-02actual | — | 2018-07-26 |
| Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea CrurisNCT02394340results2019-11-27Circulating Levels (Plasma Concentration) of Omeprazole Prior to Treatment With Luliconazole Cream 1%Open-label · Treatment | Phase 4 | Completed | Drug: Omeprazole 40 mg, Luliconazole Cream 1% | Tinea Pedis, Tinea Cruris | 20 | 2015-04-01actual | — | 2019-11-27 |
| Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT02208297results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol Etabonate Gel (BID), Vehicle Gel (BID) | Inflammation, Pain, Cataract | 326 | Mar 2015actual | — | 2020-09-25 |
| Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact LensNCT02258139results2020-09-14Percent Change in Central Corneal ThicknessOpen-label · Treatment | Not applicable | Completed | Device: B&L Investigational Contact Lens | Corneal Deformity | 38 | 2014-12-11actual | — | 2020-09-14 |
| Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT01996839results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle (BID), Vehicle (TID) | Inflammation, Pain, Cataract | 514 | May 2014actual | — | 2020-09-25 |
| Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric ParticipantsNCT01959243results2019-10-23Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Other | Phase 3 | Completed | Drug: Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Hyperemia | 507 | 2014-04-23actual | — | 2019-10-23 |
| Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.NCT02039765Plasma LevelsOpen-label · Screening | Phase 1 | Completed | Drug: Brimonidine tartrate | Hyperemia | 12 | Mar 2014actual | — | 2017-04-28 |
| Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)NCT01817582results2019-08-30Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: Lotemax, Restasis, Soothe® Lubricant Eye Drops | Keratoconjunctivitis Sicca | 102 | 2014-01-10actual | — | 2019-08-30 |
| BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT01707381results2018-09-0424 Hour IOPRandomized · Open-label · Treatment | Phase 2 | Completed | Drug: BOL-303259-X, Timolol maleate | Ocular Hypertension, Open Angle Glaucoma | 25 | Dec 2013actual | — | 2018-09-04 |
| Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular RednessNCT01959230results2019-10-23Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia ScaleRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP | Hyperemia | 60 | 2013-12-20actual | — | 2019-10-23 |
| A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry EyeNCT01791426Combined Ocular Surface Staining ScoreRandomized · Single-masked | Not applicable | Withdrawnsponsor's stated reason: Adjustment of company focus due to acquision by Valeant Pharmaceuticals | Device: Artelac Rebalance, Vismed | Dry Eye | 0 | Oct 2013actual | — | 2013-10-11 |
| Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT01591655results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mapracorat, Vehicle | Cataract, Inflammation, Surgery | 360 | Sep 2013actual | — | 2020-09-03 |
| Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male VolunteersNCT01895985intraocular pressure (IOP)Open-label · Treatment | Phase 1 | Completed | Drug: Latanoprostene bunod | Intraocular Pressure | 24 | Aug 2013actual | — | 2018-05-15 |
| Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 DaysNCT01736462Endothelial Cell DensityOpen-label | Phase 1 | Completed | Drug: Mapracorat | Corneal Endothelial Cell Changes | 61 | Jul 2013actual | — | 2013-11-26 |
| Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial ConjunctivitisNCT01740388results2014-09-17Clinical ResolutionRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Strategic business decision | Drug: Besifloxacin, Vehicle | Bacterial Conjunctivitis | 136 | Jul 2013actual | — | 2014-10-01 |
| A Study to Evaluate a Mid Add Multi-Focal Soft Contact LensNCT01959178results2020-09-30Mean Visual AcuityRandomized · Open-label · Other | Not applicable | Completed | Device: LD127025 MF, Air Optix Aqua MF | Presbyopia | 146 | Jul 2013actual | — | 2020-09-30 |
| Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryNCT01591161results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) CellsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mapracorat, Placebo | Cataract, Inflammation, Surgery | 369 | Jun 2013actual | — | 2020-09-03 |
| A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact LensNCT01873846results2019-07-24Preference Question: How Would You Say These Contact Lenses Compare Overall With the Contact Lenses You Usually Use?Open-label · Screening | Not applicable | Completed | Device: Silicone Hydrogel Contact Lens | Myopia | 400 | May 2013actual | — | 2019-07-24 |
| Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)NCT01753739results2020-09-14Mean Change From Baseline (Pre-Dose) Twice Daily Averaged Subject-rated Reflective Total Nasal Symptom Score (TNSS)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Bepotastine besilate, Placebo | Seasonal Allergic Rhinitis | 617 | Feb 2013actual | — | 2020-10-05 |
| Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial ConjunctivitisNCT01330355results2014-09-03Clinical ResolutionRandomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Lack of enrollment | Drug: Besivance, Gatifloxacin | Bacterial Conjunctivitis | 33 | Jan 2013actual | — | 2014-09-03 |
| Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single InstillationNCT01736527results2013-11-08Tear Fluid LevelsOpen-label | Phase 1 | Completed | Drug: LE Gel | Pharmacokinetics | 12 | Jan 2013actual | — | 2013-11-08 |
| Twelve Month Clinical Evaluation of KeraSoft IC Soft Contact LensesNCT01416272results2014-11-25ComfortOpen-label · Supportive care | Not applicable | Terminatedsponsor's stated reason: Study was terminated due to a business decision to cancel the entire project. | Device: KeraSoft IC Soft Contact Lenses | Keratoconus | 12 | Dec 2012actual | — | 2014-11-25 |
| Evaluation of Ocular Comfort With ISTA Tears vs SystaneNCT01650584results2020-10-06Percentage of Participants With Preference for One of the TreatmentsNon-randomized · Open-label · Treatment | Not applicable | Completed | Drug: ISTA Tears, Systane | Dry Eye Disease | 35 | Dec 2012actual | — | 2024-10-08 |
| Therapeutic Equivalence Study of Generic Brinzolamide vs AzoptNCT01722604results2021-06-09Intraocular Pressure (IOP) at Week 12Randomized · Double-masked · Health services research | Phase 3 | Completed | Drug: brinzolamide 1% ophthalmic suspension, Azopt 1% | Glaucoma, Open Angle or Ocular Hypertension | 258 | Sep 2012actual | — | 2023-05-09 |
| Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic RhinitisNCT01578278results2020-09-14Mean Change From Baseline (Pre-Dose) in Morning and Evening Averaged Subject-rated Reflective TNSSRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator | Seasonal Allergic Rhinitis | 606 | Aug 2012actual | — | 2020-10-05 |
| Evaluation of 3 Intraocular Lenses Following Lens ExtractionNCT01122576results2014-03-28Mesopic Monocular Contrast Sensitivity Without Glare 1.5 and 3 Cycles/DegreeRandomized · Double-masked · Treatment | Phase 4 | Completed | Device: Crystalens AO, ReSTOR, Tecnis Multifocal IOL | Cataract | 78 | Jun 2012actual | — | 2014-03-28 |
| A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact LensesNCT01583868results2020-10-22Visual AcuityRandomized · Single-masked · Treatment | Not applicable | Completed | Device: B&L RD2135-01 lens C, B&L RD2135-01 lens D, PureVision2, Air Optix Aqua | Myopia | 216 | Jun 2012actual | — | 2020-10-22 |
| Safety and Effectiveness of the Akreos Toric Intraocular Lens.NCT00825513Reduction of cylinder, Lens axis misalignment as determined by a photographic method.Randomized · Single-masked · Treatment | Phase 4 | Completed | Device: Akreos Toric IOL, Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO) | Cataract, Astigmatism | 198 | Mar 2012actual | — | 2013-03-25 |
| A Study to Evaluate the Feasibility of a High Add Multi Focal Contact LensNCT01518868results2020-09-30Visual AcuityRandomized · Double-masked · Treatment | Not applicable | Completed | Device: Investigational contact lens, PureVision contact lens | Presbyopia | 126 | Feb 2012actual | — | 2020-09-30 |
| A Study to Evaluate the Product Performance of a Low Add MultiFocal Soft Contact LensNCT01539694results2020-09-30Visual AcuityRandomized · Double-masked · Screening | Not applicable | Completed | Device: LD118033 contact lens, PureVision multifocal contact lens | Presbyopia | 126 | Feb 2012actual | — | 2020-09-30 |
| Toric Intraocular Lens Following Cataract SurgeryNCT01140477results2014-08-22Percent Reduction in Absolute CylinderRandomized · Single-masked · Treatment | Not applicable | Completed | Device: Toric Accommodating Lens, Accommodating Lens | Cataract, Astigmatism | 229 | Dec 2011actual | — | 2014-09-08 |
| Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to VehicleNCT01175590results2013-05-01Ocular Treatment Emergent Adverse EventsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Besivance, Vehicle | Bacterial Conjunctivitis | 518 | Dec 2011actual | — | 2013-05-01 |
| A Study to Evaluate the Safety and Efficacy of a New Silicone Hydrogel Contact Lens DesignNCT01449526results2015-02-18Visual Acuity (VA)Randomized · Double-masked | Not applicable | Completed | Device: B&L Investigational Contact Lens, B&L PureVision Contact Lens | Myopia | 166 | Dec 2011actual | — | 2015-02-18 |
| Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular HypertensionNCT01223378results2018-07-24Change in Mean Diurnal IOP at Visit 6 (Day 28)Randomized · Single-masked · Screening | Phase 2 | Completed | Drug: BOL-303259-X, Latanoprost | Intraocular Pressure | 413 | 2011-12-20actual | — | 2018-07-24 |
| Accommodation Measurements After Bilateral Implantation of an Aspheric Accommodating Lens and Monofocal Aspheric LensesNCT01241279results2014-11-26Amplitude of AccommodationRandomized · Double-masked · Treatment | Phase 4 | Terminatedsponsor's stated reason: Terminated due to low enrollment | Device: Crystalens AO, SoftPort LI61AO | Cataract | 6 | Nov 2011actual | — | 2014-11-26 |
| Safety and Efficacy of a Contact Lens for Daily Disposable UseNCT01365039results2014-01-08Slit Lamp Findings > Grade 2Randomized · Single-masked | Not applicable | Completed | Device: Test, daily disposable contact lens, SofLens daily disposable contact lens | Myopia | 173 | Oct 2011actual | — | 2014-01-08 |
| Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract SurgeryNCT01298752results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated. | Drug: Mapracorat, Vehicle | Inflammation, Pain, Cataract | 177 | Sep 2011actual | — | 2020-09-03 |
| A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact LensNCT01412983results2014-04-29Visual AcuityRandomized · Single-masked · Screening | Not applicable | Completed | Device: Bausch & Lomb Test lens, Ciba Vision soft contact lens | Myopia | 100 | Sep 2011actual | — | 2014-04-29 |
| A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye DiseaseNCT01212471results2020-09-04Mean Ocular Surface Disease Index (OSDI) Total ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator | Dry Eye Syndrome | 840 | Aug 2011actual | — | 2020-09-04 |
| A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact LensNCT01416142results2013-12-25Visual AcuityRandomized · Open-label · Treatment | Not applicable | Completed | Device: PureVision2 HD contact lenses, Spectacles | Myopia | 63 | Aug 2011actual | — | 2013-12-25 |
| Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryNCT01367249results2014-05-06Ocular InflammationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac Ophthalmic Solution, Placebo | Pain, Inflammation, Cataract | 440 | Jul 2011actual | — | 2014-05-06 |
| Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye SyndromeNCT01163643results2020-09-03Mean Corneal Staining ScoreRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM | Dry Eye Syndrome | 356 | Jun 2011actual | — | 2020-09-25 |
| Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens ExtractionNCT01225952results2013-01-18Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree)Randomized · Double-masked · Treatment | Phase 4 | Completed | Device: Crystalens AO, ReSTOR 3.0, AMO Tecnis Multifocal | Cataract | 93 | Jun 2011actual | — | 2013-01-18 |
| Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract SurgeryNCT01230125results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Mapracorat, Vehicle | Cataract | 311 | Jun 2011actual | — | 2020-09-03 |
| A Study to Evaluate a Modified Contact LensNCT01391364results2020-09-30Percentage of Eyes With > Grade 2 Slit Lamp FindingsRandomized · Double-masked · Treatment | Not applicable | Completed | Device: SofLens in investigational solution, SofLens in currently marketed solution | Myopia | 438 | Jun 2011actual | — | 2020-09-30 |
| Mapracorat Ophthalmic Formulation in Subjects With Allergic ConjunctivitisNCT01289431results2020-09-04Ocular ItchingRandomized · Double-masked · Prevention | Phase 2 | Completed | Drug: Mapracorat, Vehicle | Conjunctivitis, Allergic | 236 | Apr 2011actual | — | 2020-09-04 |
| Study of A New Contact Lens Cleaning and Disinfecting SolutionNCT01318577results2020-10-08Percentage of Eyes With > Grade 2 Slit Lamp FindingsRandomized · Double-masked · Prevention | Not applicable | Completed | Device: Investigational Cleaning & Disinfecting Solution, Clear Care Solution | Vision Disorders | 444 | Apr 2011actual | — | 2020-10-08 |
| Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)NCT01435460results2012-03-13Bulbar Conjunctival InjectionRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol etabonate 0.2%, Olopatadine 0.1% | Seasonal Allergic Conjunctivitis | 300 | Apr 2011actual | — | 2012-03-13 |
| Evaluation of Two Daily Disposable Contact Lenses.NCT01300065results2020-10-06Percentage of Eyes With > Grade 2 Slit Lamp FindingsRandomized · Double-masked · Other | Not applicable | Completed | Device: Experimental- Soflens, Marketed - Soflens | Myopia | 441 | Mar 2011actual | — | 2020-10-06 |
| Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens WearersNCT01317030results2020-01-09observationalHyaluronan Levels | — | Terminatedsponsor's stated reason: Study was terminated due to a business decision to cancel the entire project. | Device: Contact Lens Wear, Contact Lens Wear · Other: Non-Contact Lens Wear | Dry Eye | 25 | Mar 2011actual | — | 2020-01-09 |
| Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic RhinitisNCT01277341results2020-09-14Mean Change From Baseline (Pre-Dose) in Subject-rated Reflective TNSSRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Bepotastine Besilate Nasal Spray 2% Twice a day, Bepotastine Besilate Nasal Spray 3% Twice a day, Bepotastine Besilate Nasal Spray 4% Twice a day, Placebo Nasal Spray | Seasonal Allergic Rhinitis | 601 | Feb 2011actual | — | 2020-10-05 |
| A Study to Evaluate the Performance of Two Designs of Soft Toric LensesNCT01309867results2020-10-08Percentage of Eyes With Absolute Lens Rotation ≤ 10 Degrees.Randomized · Single-masked · Other | Not applicable | Completed | Device: Investigational Toric Lens, PureVision Toric Lens | Myopia | 302 | Feb 2011actual | — | 2020-10-08 |
| One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract ExtractionNCT01230060results2013-08-22Visual AcuityOpen-label · Treatment | Phase 3 | Completed | Device: enVista | Aphakia, Cataract | 122 | Jan 2011actual | — | 2013-08-22 |
| A Study to Evaluate a New Silicone Hydrogel Contact LensNCT01309893results2014-11-24Distance High Contrast logMAR Visual Acuity at 1 WeekRandomized · Single-masked | Not applicable | Completed | Device: Investigational Lens, Air Optix Aqua lens | Myopia | 66 | Jan 2011actual | — | 2014-11-24 |
| Evaluation of the Feasibility a New Silicone Hydrogel Contact LensNCT01309906results2020-10-22Visual AcuityRandomized · Single-masked · Other | Not applicable | Completed | Device: Investigational lens, Air Optix Aqua lens | Myopia | 66 | Jan 2011actual | — | 2020-10-22 |
| Study to Evaluate a Contact Lens Lubricating and Rewetting DropNCT01267656results2020-09-30Percentage of Eyes With Graded Slit Lamp Findings Greater Than Grade 2.Randomized · Single-masked · Screening | Not applicable | Completed | Device: Lubricating and Rewetting Drops, AMO Blink Contacts Lubricant Eye Drops | Dry Eye | 168 | Dec 2010actual | — | 2020-09-30 |
| Product Feasibility of a New Silicone Hydrogel Contact LensNCT01309100results2014-04-29Visual Acuity (Investigational vs Air Optix Aqua Lens)Randomized · Single-masked | Not applicable | Completed | Device: Investigational Lens, Acuvue Oasys Lens, Air Optix Aqua Lens | Myopia | 144 | Dec 2010actual | — | 2014-04-29 |
| Evaluation of a New Silicone Hydrogel Contact LensNCT01309880results2015-02-23Visual AcuityRandomized · Single-masked | Not applicable | Completed | Device: Test lens, Air Optix Aqua | Myopia | 66 | Dec 2010actual | — | 2015-02-23 |
| Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial ConjunctivitisNCT00972777results2012-03-29Clinical ResolutionRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Besifloxacin, Vehicle (Placebo) | Bacterial Conjunctivitis | 474 | Oct 2010actual | — | 2012-03-29 |
| Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis PatientsNCT01174823results2020-09-14Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total ScoreRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution | Allergic Conjunctivitis | 245 | Oct 2010actual | — | 2020-09-14 |
| A Study to Evaluate the Product Performance of a Daily Disposable Contact LensNCT01192126results2014-01-03Visual AcuityRandomized · Open-label | Not applicable | Completed | Device: Bausch & Lomb new daily disposable, Johnson & Johnson Acuvue Moist | Myopia, Contact Lenses | 102 | Oct 2010actual | — | 2014-01-03 |
| Product Performance of a Daily Disposable Contact LensNCT01230554results2019-08-14Market Research SurveyOpen-label · Other | Not applicable | Completed | Device: Daily disposable cosmetic tint lens | Myopia | 212 | Oct 2010actual | — | 2019-08-28 |
| Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryNCT01060072results2012-01-13Resolution of Anterior Chamber Cells.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol etabonate, Vehicle of Loteprednol Etabonate | Inflammation, Pain | 407 | Sep 2010actual | — | 2012-01-13 |
| Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy VolunteersNCT01159015results2020-09-14Percentage of Participants With at Least One Adverse Event.Randomized · Triple-masked · Screening | Phase 3 | Completed | Drug: KetoNaph, Vehicle | Allergic Conjunctivitis | 534 | Sep 2010actual | — | 2020-10-05 |
| Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental ChamberNCT01222299results2020-09-14Mean Change From Baseline (Pre-Dose) in Subject-rated Instantaneous TNSSRandomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: bepotastine besilate nasal product - low dose, bepotastine besilate nasal product - medium dose, bepotastine besilate nasal product - high dose, placebo comparator nasal product | Seasonal Allergic Rhinitis | 89 | Aug 2010actual | — | 2020-10-05 |
| Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract SurgeryNCT01010633results2012-01-09Resolution of Anterior Chamber Cells (ACC).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vehicle of Loteprednol Etabonate, Loteprednol Etabonate | Inflammation, Pain | 406 | Jun 2010actual | — | 2012-01-09 |
| Evaluation of Two Different Designs of Bausch & Lomb Contact LensesNCT01118338results2020-10-06Symptoms and ComplaintsRandomized · Double-masked · Basic science | Not applicable | Completed | Device: Redesigned Purevision Contact Lens, PureVision Contact Lens | Myopia | 376 | Jun 2010actual | — | 2020-10-06 |
| A Study to Assess the Safety and Efficacy of a Daily Disposable Contact LensNCT01130974results2013-12-10Slit Lamp FindingsRandomized · Open-label · Treatment | Not applicable | Completed | Device: Bausch & Lomb contact lens, Marketed daily disposable contact lens | Myopia | 200 | Jun 2010actual | — | 2013-12-10 |
| Feasibility of a New Silicone Hydrogel LensNCT01131130results2014-04-30Comfort Throughout the Day - Test Lens vs. Air Optix Aqua LensRandomized · Single-masked | Not applicable | Completed | Device: Investigational contact lens, Acuvue Oasys Contact Lens, Air Optix Aqua | Myopia | 120 | Jun 2010actual | — | 2014-04-30 |
| Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular Lens.NCT00804726Visual acuityNon-randomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Test lens did not meet near visual efficacy endpoints | Device: Akreos MI Five-O | Cataract | 10 | May 2010actual | — | 2014-01-17 |
| Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen ChallengeNCT01107405results2012-03-21Ocular ItchingRandomized · Double-masked · Prevention | Phase 2 | Completed | Drug: Loteprednol etabonate base (QD), Loteprednol etabonate base (BID), Loteprednol etabonate base (QID), Loteprednol etabonate suspension, Vehicle of loteprednol etabonate | Allergic Conjunctivitis | 101 | May 2010actual | — | 2012-03-21 |
| Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.NCT00770133results2020-10-27Ocular ItchingRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ketotifen/naphazoline, Naphazoline, Ketotifen, Vehicle | Allergic Conjunctivitis | 141 | Apr 2010actual | — | 2020-10-27 |
| Co-Axial Micro-Incision Versus Co-Axial Small Incision Cataract Surgery Using the Stellaris Enhancement SystemNCT01261975results2012-02-27Refractive StabilityRandomized · Single-masked · Treatment | Phase 4 | Completed | Procedure: Coaxial Micro-Incision Cataract Surgery, Coaxial Small Incision Cataract Surgery | Cataract, Aphakia | 36 | Apr 2010actual | — | 2012-02-27 |
| Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric BlepharoconjunctivitisNCT00705159results2011-08-11Change From Baseline in the Total Blepharoconjunctivitis Grade.Randomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: loteprednol etabonate and tobramycin, loteprednol etabonate, Tobramycin, Vehicle of Zylet | Conjunctivitis | 137 | Mar 2010actual | — | 2015-03-24 |
| Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatment of Myopia and Myopic Astigmatism.NCT00769808results2020-09-11Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or BetterOpen-label · Treatment | Not applicable | Completed | Device: Bausch & Lomb 217z Excimer Laser | Myopia, Astigmatism | 72 | Mar 2010actual | — | 2020-09-11 |
| Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract SurgeryNCT00905450results2020-09-03Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: BOL-303242-X, Vehicle for BOL-303242-X | Cataract, Inflammation | 415 | Mar 2010actual | — | 2020-09-22 |
| Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of BlepharokeratoconjunctivitisNCT01028027results2011-09-15Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP PopulationRandomized · Single-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol and tobramycin, Tobramycin and dexamethasone | Conjunctivitis, Keratitis, Blepharitis | 357 | Feb 2010actual | — | 2012-02-28 |
| A Study to Evaluate the Clinical Performance of a Novel Multipurpose SolutionNCT01024751results2011-08-11Comfort-related Symptoms/ComplaintsRandomized · Single-masked · Supportive care | Not applicable | Completed | Device: Bausch & Lomb Multi-Purpose Solution, Ciba's Multi-Purpose Solution | Ocular Discomfort | 312 | Jan 2010actual | — | 2011-08-15 |
| Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens WearersNCT00985231results2011-03-14Distance Visual Acuity (VA) Between Test and Control Lenses Worse Than 20/40.Randomized · Single-masked · Treatment | Not applicable | Completed | Device: PureVision Multi-Focal contact lenses, SofLens59 contact lens | Vision Disorders | 272 | Nov 2009actual | — | 2015-03-24 |
| Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract SurgeryNCT00853970results2011-01-26Summed Ocular Inflammation Score (SOIS) of ZeroRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac Ophthalmic Solution, Placebo Comparator | Pain, Inflammation | 299 | Sep 2009actual | — | 2013-01-25 |
| Study of T-PRED(TM) Compared to Pred Forte(R) IINCT00854061results2020-10-20Means Aqueous Humor Prednisolone Acetate ConcentrationRandomized · Quadruple-masked · Basic science | Phase 3 | Completed | Drug: T-Pred, Pred Forte | Cataract | 172 | Aug 2009actual | — | 2020-10-20 |
| Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of SubjectsNCT00824070results2010-10-29The Aqueous Humor Drug Concentration.Randomized · Open-label · Screening | Phase 1 | Completed | Drug: Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin | Cataract Extraction | 105 | Jul 2009actual | — | 2011-12-13 |
| Ocular Responses to Short and Long-term Lens WearNCT00722891Quantify the ocular response to acute and chronic lens wear using slit lamp examination, tear assay and corneal sensitivity.Randomized · Double-masked · Basic science | Not applicable | Completed | Device: Purevision Lenses with ReNu Multiplus, Purevision Lenses with Optifree RepleniSH | Ametropia | 30 | Jun 2009actual | — | 2019-11-26 |
| Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract SurgeryNCT00904904Aqueous flareRandomized · Single-masked · Prevention | Phase 4 | Completed | Drug: Indomethacin ophthalmic solution, Ketorolac Ophthalmic Solution | Cataract, Inflammation | 120 | Jun 2009actual | — | 2012-08-13 |
| Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract SurgeryNCT00699153results2010-09-23Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate | Ocular Inflammation | 400 | May 2009actual | — | 2015-03-24 |
| Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical InstillationNCT00905762Concentration of besifloxacin, gatifloxacin or moxifloxacin in conjunctival tissue.Randomized · Double-masked · Screening | Phase 1 | Completed | Drug: Gatifloxacin, Moxifloxacin, Besifloxacin | Healthy | 119 | Apr 2009actual | — | 2011-12-09 |
| Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract SurgeryNCT00645671results2010-09-23Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment, Vehicle of Loteprednol Etabonate Ophthalmic Ointment | Ocular Inflammation | 400 | Mar 2009actual | — | 2015-03-24 |
| Evaluation of a Multi-Purpose SolutionNCT00710879results2011-02-08Antimicrobial EfficacyNon-randomized · Open-label · Supportive care | Not applicable | Completed | Device: Bausch & Lomb Multi-Purpose Solution | Contact Lens Solutions | 180 | Feb 2009actual | — | 2011-12-13 |
| A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for HyperopiaNCT00348205results2020-09-14Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 MonthsOpen-label · Treatment | Not applicable | Completed | Device: Technolas 217z Zyoptix Laser | Hyperopia, Astigmatism | 80 | Jan 2009actual | — | 2020-09-14 |
| Pediatric Zylet Safety and Efficacy StudyNCT00420628results2010-09-22Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: loteprednol etabonate/tobramycin opthalmic suspension, vehicle | Chalazion, Hordeolum | 108 | Jan 2009actual | — | 2011-10-07 |
| Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract SurgeryNCT00704418results2011-01-26Number of Participants With Summed Ocular Inflammation Score (SOIS) of ZeroRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac, Placebo | Cataract | 156 | Jan 2009actual | — | 2013-01-18 |
| Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseNCT00758784results2020-09-14Mean Change From Baseline in Average Lissamine Green Staining in the Study EyeOpen-label · Treatment | Phase 2 | Completed | Drug: bromfenac ophthalmic solution 0.06% | Dry Eye Disease | 38 | 2009-01-14actual | — | 2020-09-14 |
| Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.NCT00769886results2020-10-27Ocular ItchingRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle | Allergic Conjunctivitis | 144 | Dec 2008actual | — | 2024-04-03 |
| A Product Performance Evaluation of a Novel Contact Lens for Daily Disposable UseNCT00784641results2020-10-06Percentage of Participants With Favorable Responses for the Initial Lens Performance SurveyRandomized · Open-label · Supportive care | Not applicable | Completed | Device: Novel Bausch & Lomb daily disposable contact lenses, Bausch & Lomb SofLens daily disposable contact lenses., Johnson and Johnson 1-Day Acuvue Moist contact lenses | Myopia | 567 | Dec 2008actual | — | 2020-10-06 |
| Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract SurgeryNCT00703781results2011-12-09Number of Participants With Summed Ocular Inflammation Score (SOIS) of ZeroRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: bromfenac ophthalmic solution, placebo | Cataract | 126 | Nov 2008actual | — | 2015-03-24 |
| One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact LensNCT00902850results2015-03-02Clinical PerformanceRandomized · Double-masked · Treatment | Not applicable | Completed | Device: SofLens Daily Disposable, Marketed 1 Day Contact Lens | Myopia | 28 | Nov 2008actual | — | 2015-03-02 |
| Comparative Study of the Wearing Satisfaction of Two Soft Contact Lens Designs.NCT00768885Patient satisfactionRandomized · Open-label · Screening | Not applicable | Completed | Device: PureVision 1, PureVision 2 | Myopia | 64 | Oct 2008actual | — | 2013-03-18 |
| Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye DiseaseNCT00667004results2020-09-03Mean Change From Baseline in Lacrimation Assessed by Schirmer's TestRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: ecabet ophthalmic solution, placebo | Dry Eye Disease | 183 | 2008-09-12actual | — | 2020-09-03 |
| Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose SolutionNCT00636363results2011-04-08Slit-lamp Findings > Grade 2Randomized · Double-masked · Supportive care | Not applicable | Completed | Device: Bausch & Lomb Multipurpose Solution - Rub Care, Bausch & Lomb Multipurpose Solution - No Rub Care, Ciba Vision Aquify Multipurpose Solution | Contact Lens Solutions | 541 | Aug 2008actual | — | 2015-03-24 |
| Study of T-PRED(TM) Compared to Pred Forte(R)NCT00699803results2020-09-03Mean Aqueous Humor Prednisolone Acetate ConcentrationRandomized · Quadruple-masked · Basic science | Phase 2 | Completed | Drug: T-PRED, Pred Forte | Cataract | 64 | Aug 2008actual | — | 2020-09-25 |
| Efficacy and Safety of Bromfenac Ophthalmic SolutionNCT00585975results2011-12-09Number of Participants With Summed Ocular Inflammation Score (SOIS) of ZeroRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: bromfenac ophthalmic solution | Cataract Surgery | 568 | Jul 2008actual | — | 2013-02-15 |
| Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic ConjunctivitisNCT00586664results2012-03-26Ocular ItchingRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0% | Allergic Conjunctivitis | 130 | Jun 2008actual | — | 2013-02-08 |
| A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.NCT00595101results2020-08-27Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle, Latanoprost Vehicle | Primary Open Angle Glaucoma, Ocular Hypertension | 117 | Jun 2008actual | — | 2020-09-14 |
| Product Performance of a Toric Contact LensNCT00658996results2011-02-16Symptoms and ComplaintsRandomized · Open-label · Supportive care | Not applicable | Completed | Device: SofLens DD Toric, Ciba Vision Focus Dailies Toric Contact Lens | Myopia, Astigmatism | 220 | Jun 2008actual | — | 2011-12-12 |
| Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal VolunteersNCT00586625results2009-11-11Ocular ComfortRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bepreve, Placebo | Allergic Conjunctivitis | 861 | May 2008actual | — | 2013-02-15 |
| Performance of Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution in a New Packaging ConfigurationNCT00659815results2010-11-15ComfortRandomized · Single-masked · Supportive care | Not applicable | Completed | Device: Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle., Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle. | Comfort | 312 | May 2008actual | — | 2011-12-12 |
| Comparative Performance of PureVision, Acuvue Oasys and O2OptixNCT00640341results2011-03-31Any Slit Lamp Finding > Grade 2Randomized · Single-masked · Supportive care | Phase 4 | Completed | Device: PureVision Contact Lens, Acuvue Oasys Contact Lens, O2Optix Contact lens | Myopia | 510 | Apr 2008actual | — | 2011-12-12 |
| Evaluation of the Safety & Effectiveness of the Bausch & Lomb AKREOS® TL Intraocular LensNCT00838045Bast Corrected Visual AcuityOpen-label · Treatment | Phase 4 | Completed | Device: The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL | Cataract, Aphakia | 125 | Apr 2008actual | — | 2011-12-09 |
| Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose SolutionNCT00636194results2011-02-15Subjective Assessment of Comfort and CleanlinessRandomized · Double-masked · Supportive care | Not applicable | Completed | Device: Bausch & Lomb Multipurpose Solution, Alcon OptiFree Replenish Multipurpose Solution | Adverse Effect of Contact Lens Solution | 361 | Mar 2008actual | — | 2011-12-13 |
| Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for GlaucomaNCT00441883results2020-08-27Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: PF-03187207 and Latanoprost Vehicle, Latanoprost 0.005% and PF-03187207 Vehicle | Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma | 176 | Feb 2008actual | — | 2020-09-14 |
| Comparative Performance of PureVision Lens DesignsNCT00661687results2010-10-15Subjective Responses to Symptoms/ComplaintsRandomized · Double-masked · Treatment | Phase 3 | Completed | Device: Currently Marketed PureVision Contact Lens., Alternate Design of the PureVision Contact Lens. | Myopia | 206 | Feb 2008actual | — | 2011-12-12 |
| Clinical Evaluation of a New Aspheric Intraocular Lens.NCT00786565results2011-01-05Low Contrast Best Corrected Visual Acuity Following Cataract SurgeryRandomized · Single-masked | Phase 4 | Completed | Device: Advanced Akreos Adapt in one operated eye., Akreos Adapt in fellow operated eye. | Cataract | 75 | Jan 2008actual | — | 2011-12-12 |
| A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.NCT00347932results2009-08-13Clinical Resolution of Baseline Bacterial ConjunctivitisRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: ISV-403, Vehicle | Acute Bacterial Conjunctivitis | 957 | Nov 2007actual | — | 2015-03-24 |
| Systemic Pharmacokinetics of BOL-303224-ANCT00407589Assessment of systemic pharmacokinetics following a single dose and steady-state pharmacokinetics after multiple TID dosingOpen-label · Treatment | Phase 1 | Completed | Drug: BOL-303224-A | Conjunctivitis, Bacterial | 24 | Oct 2007actual | — | 2011-12-09 |
| Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 DaysNCT01120418Endothelial cell density change between treatment group.Randomized · Open-label · Screening | Phase 1 | Completed | Drug: Besifloxacin Ophthalmic Suspension 0.6% | Healthy | 120 | Oct 2007actual | — | 2012-08-13 |
| Study to Evaluate Plasmin for the Creation of a Posterior Vitreous DetachmentNCT00348439Presence of a Grade A Posterior Vitreous Detachment (PVD)Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Lack of Efficacy | Drug: Plasmin, Vehicle | Vitreoretinal Traction Syndrome | 29 | Aug 2007actual | — | 2019-06-21 |
| Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic ConjunctivitisNCT00423007Treatment of ocular itchingRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac, Placebo | Allergic Conjunctivitis | 90 | Aug 2007actual | — | 2013-03-14 |
| A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial ConjunctivitisNCT00348348results2009-08-13Clinical ResolutionRandomized · Triple-masked · Treatment | Phase 3 | Completed | Drug: Besifloxacin, Moxifloxacin solution | Acute Bacterial Conjunctivitis | 1,161 | Jul 2007actual | — | 2015-03-24 |
| Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic ConjunctivitisNCT00424398results2012-03-26Ocular ItchingRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Bepreve, Placebo, Bepotastine Besilate | Conjunctivitis, Allergic | 107 | Jul 2007actual | — | 2013-02-15 |
| Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye SyndromeNCT00370747Ocular signs and SymptomsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Ecabet, Ecabet, Placebo | Dry Eye Syndromes | 162 | Jun 2007actual | — | 2013-03-15 |
| Zylet vs TobraDex in BlepharokeratoconjunctivitisNCT00447577The primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite scoreRandomized · Single-masked · Treatment | Phase 4 | Completed | Drug: Loteprednol etabonate and tobramycin ophthalmic suspension, Tobramycin and dexamethasone ophthalmic suspension | Blepharokeratoconjunctivitis | 276 | Jun 2007actual | — | 2011-12-09 |
| A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)NCT00347646Presence of a Posterior Vitreous Detachment (PVD)Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Lack of Efficacy | Drug: Plasmin | Vitreoretinal Traction Syndrome | 4 | May 2007actual | — | 2019-06-21 |
| Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract SurgeryNCT00333918Reduction of ocular inflammationRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: bromfenac ophthalmic solution, placebo comparator | Pain, Inflammation | 522 | Mar 2007actual | — | 2013-02-15 |
| Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous DetachmentNCT00198471Vitreous detachmentOpen-label · Treatment | Phase 2 | Completed | Drug: Vitrase | Vitreous Detachment, Diabetic Retinopathy | 10 | Nov 2006actual | — | 2013-03-15 |
| A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)NCT00347594Measurement of aberrations with the NGDI and the Zywave II.Non-randomized · Open-label · Diagnostic | Not applicable | Completed | Device: Next Generation Diagnostic Instrument (NGDI), Zyoptix Diagnostic Workstation (ZDW) | Healthy | 76 | Sep 2006actual | — | 2014-01-17 |
| Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular EdemaNCT00502541A change from baseline in visual acuity using ETDRS charts • Humphrey Visual Field Mean Defect (24-2) • Masked reading of the size of the area of retinal thickening on color photographs and OCT, where available, and of severity of fluorescein leakageRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: fluocinolone acetonide · Procedure: Standard of Care | Diabetic Macular Edema | 196 | Sep 2006actual | — | 2013-11-28 |
| Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant vs Standardized TherapyNCT00468871Time to first occurrence of uveitis in the study eye.Randomized · Open-label · Treatment | Phase 2/3 | Completed | Drug: fluocinolone acetonide intravitreal implant, corticosteroids and immunosuppressants | Non-infectious Uveitis | 140 | Jun 2006actual | — | 2011-12-08 |
| Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular EdemaNCT00576459Between group difference in mean visual acuity change (from baseline)Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: 0.59 mg fluocinolone acetonide intravitreal implant, 2.1 mg fluocinolone acetonide intravitreal implant · Procedure: standard of care laser photocoagulation | Diabetic Macular Edema | 40 | Jun 2006actual | — | 2011-12-08 |
| Safety and Efficacy of Fluocinolone Acetonide Intravitreal ImplantNCT00456482Recurrence of uveitis before and after implantation. Postimplantation recurrences were evaluated using protocol-defined criteria based upon changes in VA, vitreous haze, and the presence of cells in the anterior chamber of the eye.Randomized · Double-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: SARS epidemic in Asia and Canada | Drug: Fluocinolone Acetonide 0.59mg, Fluocinolone Acetonide 2.1mg | Non-infectious Uveitis | 239 | Apr 2006actual | — | 2011-12-08 |
| A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractive Surgery Treatments for MyopiaNCT00365677Uncorrected visual acuityRandomized · Single-masked · Treatment | Not applicable | Completed | Device: The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm, The Bausch & Lomb Zyoptix Tissue Saving algorithm | Myopia, Astigmatism | 127 | Mar 2006actual | — | 2011-12-08 |
| Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry EyeNCT00560638Ocular discomfort during CAE exposureRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: loteprednol etabonate ophthalmic suspension, 0.5%, loteprednol etabonate ophthalmic suspension, 0.5%, vehicle of loteprednol etabonate | Dry Eye | 119 | Feb 2006actual | — | 2011-07-18 |
| Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye SyndromeNCT00198536Ocular discomfortRandomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Ecabet 2.83%, Ecabet 3.70%, Vehicle | Dry Eye Syndromes | 159 | Dec 2005actual | — | 2013-03-14 |
| A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForteNCT00198523Bioequivalence will be measured by comparing aqueous humor concentrations of prednisolone acetate at various time pointsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Prednisolone and Tobramycin, Prednisolone | Eye Infections, Postoperative Complications | 132 | Oct 2005actual | — | 2013-03-15 |
| Safety and Efficacy of Fluocinolone Acetonide Intravitreal ImplantsNCT00407082Recurrence of uveitis before and after implantation.Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg | Noninfectious Posterior Uveitis | 278 | Sep 2005actual | — | 2011-12-08 |
| Clinical and Microbial Efficacy of ISV403 in Bacterial ConjunctivitisNCT00622908results2009-08-13Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: ISV-403, Vehicle | Bacterial Conjunctivitis | 270 | Jun 2005actual | — | 2015-03-24 |
| Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus TobradexNCT00532961Ocular comfort/tolerabilityRandomized · Quadruple-masked · Treatment | Phase 4 | Completed | Drug: Loteprednol etabonate 0.5% and tobramycin 0.3%, Dexamethasone 0.1% and tobramycin 0.3% | Inflammation | 310 | Apr 2005actual | — | 2011-12-08 |
| Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected AnestheticsNCT00198549To evaluate physician acceptance of efficacy of Vitrase as an adjuvant to increase absorption and dispersion of anesthetics used for ophthalmic surgical proceduresOpen-label · Treatment | Phase 4 | Completed | Drug: Vitrase (ovine hyaluronidase) Lyophilized | Pain | 40 | Jan 2005actual | — | 2013-03-19 |
| Evaluation of Vitrase as a Spreading AgentNCT00198484Physician Satisfaction SurveyOpen-label · Treatment | Phase 3 | Completed | Drug: Vitrase | Pain | 108 | Dec 2004actual | — | 2013-03-14 |
| Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)NCT00198458HypersensitivityOpen-label | Phase 1 | Completed | Drug: Vitrase | Drug Hypersensitivity | 65 | Jul 2004actual | — | 2013-03-18 |
| Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)NCT00198419HypersensitivityOpen-label · Screening | Phase 1 | Completed | Drug: Vitrase | Drug Hypersensitivity | 65 | Mar 2004actual | — | 2013-03-14 |
| Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract SurgeryNCT00198445Ocular Inflammation ScoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Bromfenac, Placebo | Postoperative Complications, Cataract | 527 | Jan 2004actual | — | 2013-03-14 |
| Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198497Vitreous hemorrhage resolutionRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Vitrase, Vitrase | Vitreous Hemorrhage, Diabetic Retinopathy | 510 | Sep 2001actual | — | 2013-03-15 |
| Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous HemorrhageNCT00198510Resolution of Vitreous HemorrhageRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Vitrase, Vitrase, Vitrase | Vitreous Hemorrhage, Diabetic Retinopathy | 750 | Sep 2001actual | — | 2013-03-15 |
| A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for LasikNCT00347997Visual acuityNon-randomized · Open-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Decision made by B\&L to cancel the study, no subjects enrolled. | Device: 217z Laser | Myopia, Astigmatism | 0 | — | — | 2011-12-08 |
| A Study Of The Safety And Effectiveness Of A New Treatment For Allergic ConjunctivitisNCT00375596Safety and efficacy of a new allergy medication | Phase 2 | Withdrawnsponsor's stated reason: Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project. | Drug: Ketotifen/vasoconstrictor | Allergic Conjunctivitis | 0 | — | — | 2015-02-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19